A Phase 1 Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RB006 Administered Subcutaneously, With and Without IV RB007, in Healthy Young Volunteers

Trial Profile

A Phase 1 Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RB006 Administered Subcutaneously, With and Without IV RB007, in Healthy Young Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2014

At a glance

  • Drugs Anivamersen-pegnivacogin (Primary) ; Pegnivacogin
  • Indications Acute coronary syndromes; Venous thrombosis
  • Focus Adverse reactions
  • Sponsors Regado Biosciences
  • Most Recent Events

    • 23 Jun 2014 Data from this study were published in the Journal of Thrombosis and Thrombolysis, according to a Regado media release.
    • 10 Jun 2013 New source identified and integrated: ClinicalTrials.gov record.
    • 15 Nov 2010 Results were presented at the American Heart Association (AHA) Scientific Sessions meeting, according to a Regado Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top